Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric ceftolozane/tazobactam plus metronidazole versus meropenem for complicated intra-abdominal infection
2016-004820-41Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- May 2017
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Intra-abdominal infection (IAI) comparing Ceftolozane/tazobactam plus metronidazole with Meropenem (2 arms). Primary endpoint: Adverse events. Started May 2017; status: completed.
02
Drugs
ceftolozanetazobactammetronidazolemeropenem
03
Conditions
Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on 2016-004820-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004820-41.